Physician
DR Q Pain & Spine Clinic, PA
DR Q Pain & Spine Clinic, PA was paid $6.48M by Medicaid between Jan 2018 and Dec 2024, across 58 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 18% of everything it billed.
33Billing provider infoDR Q PAIN & SPINE CLINIC, PA
LITTLE ROCK, AR 72205
LITTLE ROCK, AR 72205
33aNPI1477781425assigned 06/29/2009
33bProvider typePhysical Medicine & Rehabilitation Physician
28Total paid$6.48M
24GClaims400,650
24DCodes billed58
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Physical Medicine & Rehabilitation Physician providers in Arkansas
Rank by total paid#1 of 30
Median peer was paid$8K
This provider vs. median798×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,927 | $808K | |
| 2019 | 51,100 | $917K | |
| 2020 | 68,948 | $920K | |
| 2021 | 58,854 | $836K | |
| 2022 | 57,699 | $1.03M | |
| 2023 | 72,515 | $1.34M | |
| 2024incomplete | 43,607 | $629K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 41,683 | 28,102 | $1.17M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 14% | 56,347 | 45,242 | $904K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 46,476 | 30,110 | $806K |
| 64636 | 6.8% | 859 | 505 | $441K | |
| 64635 | 4.4% | 872 | 510 | $284K | |
| 64493 | 4.3% | 3,633 | 2,327 | $279K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.6% | 5,757 | 3,782 | $232K |
| 80356 | 2.7% | 9,827 | 8,949 | $177K | |
| 20552 | 2.0% | 5,373 | 3,636 | $131K | |
| 80346 | 2.0% | 10,102 | 9,205 | $131K | |
| 80348 | 1.9% | 10,288 | 9,387 | $123K | |
| 64494 | 1.9% | 3,551 | 2,301 | $120K |
46 more codes
| 64495 | 1.8% | 3,026 | $114K | |
| 80354 | 1.7% | 10,278 | $110K | |
| 80345 | 1.6% | 8,155 | $102K | |
| 80332 | 1.5% | 7,903 | $100K | |
| 80336 | 1.5% | 7,902 | $98K | |
| 80358 | 1.5% | 10,274 | $95K | |
| 80325 | 1.5% | 9,217 | $95K | |
| 80361 | 1.4% | 10,328 | $89K | |
| 80353 | 1.3% | 9,817 | $87K | |
| 80349 | 1.3% | 9,834 | $83K | |
| 80359 | <1% | 9,795 | $61K | |
| 80363 | <1% | 10,122 | $60K | |
| 80355 | <1% | 7,785 | $56K | |
| 80365 | <1% | 10,331 | $56K | |
| 27096 | <1% | 371 | $54K | |
| 80360 | <1% | 9,578 | $52K | |
| 80321 | <1% | 7,243 | $52K | |
| 80372 | <1% | 10,244 | $47K | |
| 80373 | <1% | 10,245 | $44K | |
| 01936 | <1% | 567 | $33K | |
| 83992 | <1% | 9,792 | $29K | |
| 76942 | <1% | 1,586 | $28K | |
| 80370 | <1% | 7,870 | $27K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 3,608 | $22K |
| 80366 | <1% | 7,747 | $21K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 230 | $18K |
| 64490 | <1% | 139 | $13K | |
| 20611 | <1% | 188 | $8K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 161 | $7K |
| 64491 | <1% | 137 | $5K | |
| 64492 | <1% | 107 | $5K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 240 | $3K |
| 82542 | <1% | 7,609 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 140 | $2K |
| 80324 | <1% | 212 | $1K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 320 | $1K |
| 20553 | <1% | 38 | $782.62 | |
| 80364 | <1% | 82 | $353.93 | |
| 99156 | <1% | 1,146 | $171.10 | |
| 64418 | <1% | 20 | $120.45 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 208 | $77.78 |
| 99157 | <1% | 1,041 | $58.16 | |
| 99442 | <1% | 21 | $54.00 | |
| G8539 | Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment | 0% | 108 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 90 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialQURESHI, AMIR (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Amir Z Qureshi MD LTD | Las Vegas, NV | $2.38M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.